Clinical trial
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary…
NCT00060307 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00060307 |
|---|---|
| Title | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer |
| Official title | A Phase II Study of OSI-774 (NSC-718781) in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | May 1, 2003 |
| Primary completion | May 1, 2007 |
| First posted | May 7, 2003 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: